Home› Procurement News - United States ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin at ESMO, United states (456663697)

has released a tender notice for United States ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin at ESMO in United states. Interested organizations may participate until 19 Sep 2020.

Procurement News

Procurement News
News TI Ref No
456663697
News Date
19 Sep 2020
News Description
United States ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin at ESMO
Tender Deadline
⏰ 19 Sep 2020 Closing soon
News Project Location
United States
News Sector
Healthcare & Medical - Health services Tenders Healthcare and Medical Tenders
News Document Type
Procurement News
Tender Organization Name
🔒 Members only Click for more details
Unlock Full Details — Register Free
Start with receiving Free Data Samples related to your Products and Services
✓
Live Tender Updates from worldwide
✓
Access to original Tender Documents
✓
Information on Upcoming Projects & Contract Awards
✓
Bid Assistance Services
✓
Competitor Analysis & Industry Trends
✓
Daily Custom Email Alerts by Sector & Country

Similar News

View All Sectors ->

Register to View Tenders

Start Your Business Journey. Register now for 3 days Free Sample Tenders & AI Website Demo.

Already have an account? Login here

By registering you agree to our Terms & Conditions and Privacy Policy.